GSK plc (GLAXF)
| Market Cap | 75.65B |
| Revenue (ttm) | 40.74B |
| Net Income (ttm) | 4.07B |
| Shares Out | n/a |
| EPS (ttm) | 0.98 |
| PE Ratio | 18.57 |
| Forward PE | 8.22 |
| Dividend | 0.80 (4.21%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 348 |
| Average Volume | 1,263 |
| Open | 18.76 |
| Previous Close | 18.94 |
| Day's Range | 18.76 - 18.76 |
| 52-Week Range | 15.54 - 22.45 |
| Beta | 0.27 |
| RSI | 50.51 |
| Earnings Date | Jul 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE: GSK) on Monday to develop up to 12 medicines . These agreements will add significant value to Hengrui’s globalization strategy and...
FTSE Rises as US-EU Trade Deal Lifts Mood
FTSE opens higher on trade optimism; GSK signs $12bn China deal, STV issues profit warning. The post FTSE Rises as US-EU Trade Deal Lifts Mood appeared first on Investomania .
GSK Enters $12 Billion Collaboration with Hengrui Pharma
GSK Enters $12 Billion Collaboration with Hengrui Pharma
GSK strikes $12.5B licensing deal with Hengrui Pharma
Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.
GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China’s research labs are snapping up mar...
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across ...
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology | GSK Stock News
Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal
China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 m...
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK fo...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Pe...
GSK wins EU approval for drug combos containing blood cancer drug Blenrep
GSK's blood cancer drug gets EU approval for multiple myeloma
British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.
Companies Reporting: GSK, Shell, IAG
GSK, Shell and IAG are amongst the FTSE 350 and other companies reporting earnings for the week of 28 July
GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data
The US Food and Drug Administration (FDA) on Wednesday extended the review period for the Biologics License Application (BLA) for GSK plc’s (NYSE: GSK) Blenrep combinations for relapsed or refractory...
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults.
GSK gets extended review for blood cancer drug in U.S. despite negative AdCom vote
US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
European Stocks Post Small Weekly Drop; GSK Weighs on Healthcare
European stocks ended the week with a small decline, as GSK Plc’s shares weighed on the healthcare sector on a busy earnings day.
Global Stocks Recap: Alibaba, Saab, Burberry, GSK
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning
FDA panel rejects GSK's Blenrep combo due to ... Full story available on Benzinga.com
GSK Blindsided as Blenrep Stumbles Again in the US, Shares Dive
GSK shares sink after FDA panel rejects Blenrep cancer drug, raising doubts over turnaround strategy. The post GSK Blindsided as Blenrep Stumbles Again in the US, Shares Dive appeared first on Investo...
FTSE 100 Nears Record, GSK Slumps on FDA Setback
FTSE 100 nears record high as dealmaking cheers London, GSK slides on FDA Blenrep blow. The post FTSE 100 Nears Record, GSK Slumps on FDA Setback appeared first on Investomania .